These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15152455)

  • 1. [Pitfall in migraine treatment].
    Araki N
    Rinsho Shinkeigaku; 2003 Nov; 43(11):748-51. PubMed ID: 15152455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptans and migraine.
    Bateman DN
    Lancet; 2000 Mar; 355(9207):860-1. PubMed ID: 10752697
    [No Abstract]   [Full Text] [Related]  

  • 3. Features of medication overuse headache following overuse of different acute headache drugs.
    Limmroth V; Katsarava Z; Fritsche G; Przywara S; Diener HC
    Neurology; 2002 Oct; 59(7):1011-4. PubMed ID: 12370454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
    Hedenmalm K
    Lakartidningen; 2000 Jun; 97(25):3078-84. PubMed ID: 10911703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication overuse headache.
    Diener HC; Katsarava Z
    Curr Med Res Opin; 2001; 17 Suppl 1():s17-21. PubMed ID: 12463272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking forward: the expanding utility of sumatriptan and naratriptan.
    Cady R
    Cephalalgia; 2001; 21 Suppl 1():35-8. PubMed ID: 11678821
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability of sumatriptan: clinical trials and postmarketing experience.
    Allen C; Dayno J
    Cephalalgia; 2001 Oct; 21(8):855-6. PubMed ID: 11737014
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
    Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of medication overuse headache across classes of treatments for acute migraine.
    Thorlund K; Sun-Edelstein C; Druyts E; Kanters S; Ebrahim S; Bhambri R; Ramos E; Mills EJ; Lanteri-Minet M; Tepper S
    J Headache Pain; 2016 Dec; 17(1):107. PubMed ID: 27882516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
    Welch KM
    Cephalalgia; 2001; 21 Suppl 1():25-8. PubMed ID: 11678818
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naratriptan: an alternative for migraine.
    Dulli DA
    Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans.
    Katsarava Z; Diener HC; Limmroth V
    Drug Saf; 2001; 24(12):921-7. PubMed ID: 11735648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
    Göbel H; Heinze A; Stolze H; Heinze-Kuhn K; Lindner V
    Cephalalgia; 1999 Sep; 19(7):676-83; discussion 626. PubMed ID: 10524662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
    Kayser V; Aubel B; Hamon M; Bourgoin S
    Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.
    Mathew NT
    Neurol Clin; 1997 Feb; 15(1):61-83. PubMed ID: 9058397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
    Goldstein D
    Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.